Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:October 2008
End Date:October 2012

Use our guide to learn which trials are right for you!

A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer

This phase II trial is studying how well saracatinib works in treating patients with
previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.


I. To determine the 6-month survival of biomarker-positive patients with previously treated
metastatic pancreatic cancer receiving AZD0530 (saracatinib).

II. To determine the adverse events of this drug in these patients.


I. To evaluate the response rate in patients treated with this drug. II. To evaluate the
overall survival of patients treated with this drug. III. To explore the pharmacodynamic
effects of AZD0530 with optional tumor biopsies, pharmacokinetic studies, and positron
emission tomography (PET) scans in a subset of patients.


Patients receive saracatinib orally (PO) once daily (QD) on days 1-28. Courses repeat every
28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 2 years.

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the pancreas

- Metastatic disease

- Received ≥ 1 prior chemotherapy regimen, preferably gemcitabine hydrochloride-based

- Biomarker screening portion of study:

- For subjects without archival tissue available (core biopsy or resection
specimen; fine-needle aspirate samples only are not sufficient), must be willing
to undergo a fresh needle-core biopsy of a safely biopsiable metastasis

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS

- White blood cell (WBC) ≥ 3,000/mm³

- Absolute neutrophil count (ANC) ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9 g/dL

- Total bilirubin < 1.5 times upper normal limit (ULN) (patients may have been shunted
in order to achieve normal bilirubin level)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 times ULN (<
5 times ULN for patients with liver metastases)

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Urine protein < 1,000 mg

- Urine protein: creatinine ratio ≤ 1.0

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Asymptomatic human immunodeficiency virus (HIV) allowed

- Willingness to undergo 2 tumor biopsies

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to AZD0530

- No prolonged QTc interval (i.e., ≥ 480 msec)

- No other significant electrocardiogram (ECG) abnormalities

- No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 150 mm Hg or
diastolic BP ≥ 90 mm Hg)

- No concurrent cardiac dysfunction including, but not limited to, any of the following:

- History of ischemic heart disease

- Myocardial infarction

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- No condition (e.g., gastrointestinal tract disease resulting in an inability to take
oral medication or requirement for intravenous (IV) alimentation, prior surgical
procedures affecting absorption, or active peptic ulcer disease) that impairs ability
to swallow AZD0530 tablets

- No uncontrolled concurrent illness including, but not limited to any of the following:

- Ongoing or active infection

- Psychiatric illness or social situations that would limit compliance with study

- No other malignancy within the past 5 years, except curatively treated basal cell
carcinoma of the skin or carcinoma in situ of the cervix

- Recovered from all prior therapy (< grade 2) (excluding alopecia) administered within
the past 4 weeks

- At least 3 weeks since prior chemotherapy (6 weeks for carmustine or mitomycin)

- At least 4 weeks since prior radiotherapy

- More than 7 days since prior and no concurrent cytochrome P450 3A4 (CYP3A4)-active

- No ongoing adverse events (excluding alopecia) due to chemotherapy or radiotherapy
given more than 4 weeks prior to study

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

- Concurrent low molecular weight heparin or full-dose coumadin allowed

- Concurrent therapeutic hematopoietic growth factors allowed
We found this trial at
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
Madison, WI
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
Aurora, CO
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Detroit, MI
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
Jacksonville, FL
Click here to add this to my saved trials
Nedlands, Western Australia 6009
Click here to add this to my saved trials
Rochester, Minnesota 55905
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Saint Louis, MO
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
Scottsdale, AZ
Click here to add this to my saved trials